Elevated Prolactin Symptoms: What Could Be Causing It

What Counts as Elevated Prolactin

A prolactin level above the laboratory upper limit (roughly 25 ng/mL in women and 20 ng/mL in men, though reference ranges vary by assay) qualifies as hyperprolactinemia. Mild elevations between 25 and 100 ng/mL carry a broad differential. Levels above 200 ng/mL almost always indicate a macroprolactinoma, according to the Endocrine Society 2011 Clinical Practice Guideline [1].

One critical lab pitfall: the "hook effect." Very large prolactinomas can produce prolactin concentrations so high that standard immunoassays paradoxically report a falsely normal or mildly elevated result. The Endocrine Society guideline recommends requesting serial dilutions of the sample whenever a macroadenoma is visible on MRI but the prolactin level seems disproportionately low [1]. Stress, a recent meal, or vigorous exercise within 30 minutes of the blood draw can also push prolactin up transiently by 2 to 3 times the baseline. For this reason, most endocrinologists prefer a fasting, rested morning sample drawn at least one hour after waking [1].

Macroprolactin, a biologically inactive complex of prolactin bound to immunoglobulin G, accounts for up to 10% to 25% of hyperprolactinemia cases in some series [2]. Polyethylene glycol (PEG) precipitation of the sample distinguishes true monomeric hyperprolactinemia from macroprolactinemia, sparing patients from unnecessary MRIs and medications.

Drug-Induced Hyperprolactinemia: The Most Frequent Culprit

Medications are the single most common reason for elevated prolactin in clinical practice. The mechanism is straightforward: prolactin secretion from lactotroph cells in the anterior pituitary is tonically inhibited by dopamine traveling down the tuberoinfundibular pathway. Any drug that blocks dopamine D2 receptors or depletes dopamine stores removes that brake.

Typical antipsychotics such as haloperidol raise prolactin in nearly 100% of patients, while atypical agents vary widely. Risperidone and paliperidone raise prolactin in up to 70% to 100% of users, sometimes exceeding 100 ng/mL [3]. Aripiprazole, a partial D2 agonist, may actually lower prolactin. Metoclopramide and domperidone, both D2 antagonists used for nausea and gastroparesis, are well-documented offenders. Selective serotonin reuptake inhibitors (SSRIs) produce modest elevations (generally <50 ng/mL) via serotonin-mediated stimulation of prolactin release.

The practical clinical step is a thorough medication reconciliation. If a medication known to raise prolactin was started before symptoms appeared, and the prolactin level is <100 ng/mL, the Endocrine Society guideline suggests a supervised drug holiday or switch (when psychiatrically safe) before ordering an MRI [1]. If the prolactin normalizes after discontinuation, no further workup is needed.

Prolactinomas and Other Pituitary Causes

Prolactinomas are benign lactotroph adenomas and the most common secretory pituitary tumor. They account for roughly 40% of clinically significant pituitary adenomas [4]. Classification depends on size: microprolactinomas measure <10 mm in diameter, while macroprolactinomas reach 10 mm or larger.

A useful rule of thumb links prolactin level to tumor size. Microprolactinomas typically produce prolactin levels between 50 and 200 ng/mL. Macroprolactinomas commonly exceed 200 ng/mL, and giant prolactinomas (above 40 mm) can push levels into the thousands [1]. A level of 150 ng/mL with a 3-cm sellar mass should raise immediate concern for the hook effect described earlier.

Non-functioning pituitary adenomas, craniopharyngiomas, or any mass compressing the pituitary stalk can also raise prolactin by disrupting dopamine delivery to the lactotrophs. This "stalk effect" usually keeps prolactin below 100 to 150 ng/mL, helping distinguish it from a true prolactinoma [1]. The distinction matters because stalk-effect hyperprolactinemia does not respond to dopamine agonists, and the underlying mass may require surgery.

Other sellar and parasellar lesions that cause stalk compression include Rathke cleft cysts, meningiomas, and infiltrative diseases such as sarcoidosis or Langerhans cell histiocytosis.

Hypothyroidism and Prolactin

Primary hypothyroidism raises prolactin through a well-characterized feedback loop. Low circulating thyroxine (T4) triggers increased hypothalamic thyrotropin-releasing hormone (TRH) secretion. TRH stimulates not only thyroid-stimulating hormone (TSH) from thyrotrophs but also prolactin from lactotrophs. In a study published in the Journal of Clinical Endocrinology & Metabolism, hyperprolactinemia resolved completely in hypothyroid patients once levothyroxine restored euthyroidism [5].

The prolactin elevation in hypothyroidism is typically mild, ranging from 25 to 100 ng/mL. Checking TSH alongside prolactin is standard practice. Treating the thyroid disorder alone corrects the prolactin excess, and dopamine agonists are not needed.

Less Common Causes: Chest Wall, Renal, and Hepatic

Several systemic conditions raise prolactin through distinct pathways. Chronic kidney disease reduces prolactin clearance and blunts hypothalamic dopamine tone. Hyperprolactinemia is present in up to 30% of patients with end-stage renal disease [6]. Prolactin levels may partially normalize after renal transplantation but often persist in patients on long-term dialysis.

Chest wall irritation, including herpes zoster reactivation affecting thoracic dermatomes, post-thoracotomy scarring, and even nipple piercings, can stimulate the afferent neural arc that normally mediates suckling-induced prolactin release. Cirrhosis impairs hepatic estrogen metabolism, and the resulting hyperestrogenism may stimulate lactotroph hyperplasia, though this mechanism contributes modest elevations.

Seizures produce transient prolactin spikes peaking 15 to 20 minutes after the event. A prolactin level drawn within that window and exceeding twice the upper limit of normal has been used (with limited sensitivity) to differentiate generalized tonic-clonic seizures from psychogenic nonepileptic events, as described in a 2005 Neurology practice parameter [7].

Recognizing the Symptoms in Women vs. Men

Hyperprolactinemia disrupts the hypothalamic-pituitary-gonadal axis by suppressing gonadotropin-releasing hormone (GnRH) pulsatility. The downstream effects differ by sex and by the degree of prolactin elevation.

In premenopausal women, the earliest sign is often oligomenorrhea (cycles longer than 35 days), progressing to amenorrhea. Galactorrhea, the spontaneous or expressible discharge of milk outside of pregnancy or lactation, occurs in roughly 30% to 80% of hyperprolactinemic women [1]. Anovulatory infertility is a frequent presenting complaint in reproductive-age patients. Prolonged estrogen deficiency from chronic hyperprolactinemia accelerates bone mineral density loss; a cross-sectional analysis found a 25% reduction in lumbar spine bone density in amenorrheic women with prolactinomas compared to age-matched controls [8].

In men, symptoms develop more insidiously. Erectile dysfunction, decreased libido, reduced ejaculate volume, and fatigue are common. Because men lack an obvious menstrual marker, diagnosis is often delayed. By the time of presentation, men more frequently harbor macroprolactinomas with visual field defects from optic chiasm compression. Gynecomastia and galactorrhea occur in fewer than 20% of affected men. Testosterone levels are typically suppressed, and bone density may also decline.

In postmenopausal women, the absence of menses removes the most noticeable signal. Prolactinomas in this group are usually identified incidentally on imaging or when a macroadenoma produces mass-effect symptoms such as headache or bitemporal hemianopia.

Diagnostic Workup: Step by Step

The Endocrine Society guideline [1] outlines a clear algorithm. First, confirm the elevation with a repeat fasting morning prolactin level. Exclude pregnancy with a beta-hCG test. Review the medication list for D2 antagonists, antipsychotics, and other offenders.

If drug-induced hyperprolactinemia is suspected and the prolactin is <100 ng/mL, a trial discontinuation or switch (with psychiatric clearance when relevant) clarifies the picture within 72 hours. Persistent elevation warrants a TSH to rule out hypothyroidism and a comprehensive metabolic panel to screen for renal or hepatic insufficiency.

When the prolactin remains elevated after reversible causes are excluded, gadolinium-enhanced MRI of the sella is the imaging study of choice [1]. CT is inferior for small lesions and exposes the patient to ionizing radiation. Formal visual field testing (Humphrey or Goldmann perimetry) is indicated whenever the tumor abuts or compresses the optic chiasm.

Dr. Shlomo Melmed, a leading pituitary specialist at Cedars-Sinai, has stated: "A prolactin level disproportionately low for the size of the pituitary mass should always trigger a dilution study to unmask the hook effect" [1]. This single step prevents misdiagnosis and inappropriate surgery.

Treatment: Dopamine Agonists as First Line

Dopamine agonists remain the primary treatment for prolactinomas regardless of size. Cabergoline normalizes prolactin in approximately 85% of patients with microprolactinomas and in 70% of those with macroprolactinomas [9]. The starting dose is typically 0.25 mg twice weekly, titrated every four weeks based on prolactin response. Bromocriptine, the older agent, normalizes prolactin in about 70% of microprolactinomas but carries a higher side-effect burden (nausea, orthostatic hypotension, nasal congestion) and requires daily or twice-daily dosing.

A head-to-head comparison published in the New England Journal of Medicine showed cabergoline was both more effective and better tolerated than bromocriptine in women with hyperprolactinemic amenorrhea [10]. Cabergoline restored ovulatory cycles in 72% of participants versus 52% for bromocriptine. Tumor shrinkage of 50% or more occurs in a majority of macroprolactinomas within 6 to 12 months of cabergoline therapy.

Cardiac valve concerns surfaced from Parkinson's disease studies using cabergoline at doses of 3 to 7 mg daily, far above typical prolactinoma doses. A meta-analysis of 10 studies found no clinically significant valvular changes in patients receiving cabergoline at prolactinoma-range doses (under 2 mg weekly), though periodic echocardiographic monitoring remains standard practice for patients on doses above 2 mg per week or on long-term therapy [11].

Transsphenoidal surgery is reserved for patients who are intolerant of or resistant to dopamine agonists, those with apoplexy (acute hemorrhage into the tumor), or those with macroprolactinomas causing progressive visual field loss despite medical therapy. Remission rates for microprolactinomas reach 70% to 90% in experienced surgical centers, but recurrence occurs in 10% to 20% within 10 years [12].

Radiation therapy (stereotactic radiosurgery or fractionated radiotherapy) is a third-line option, usually for aggressive or recurrent tumors. It carries a 50% to 80% risk of subsequent hypopituitarism.

When to Worry and When to Reassure

Not every mildly elevated prolactin requires aggressive workup. A level of 28 ng/mL in a woman taking an SSRI, with regular cycles and no galactorrhea, is unlikely to represent a clinically meaningful problem. Repeating the level in 3 to 6 months while ensuring a stress-free, fasting morning draw is reasonable.

Red flags that demand prompt evaluation include: prolactin above 100 ng/mL without an obvious medication cause, new-onset headaches or visual field changes, amenorrhea lasting longer than 6 months, or male hypogonadal symptoms alongside a prolactin above 50 ng/mL.

The 2011 Endocrine Society guideline specifically states: "We recommend against treatment of asymptomatic microprolactinomas with dopamine agonists if the patient does not desire fertility and has normal bone density" [1]. Observation with annual prolactin measurement and MRI surveillance is appropriate in those cases.

Long-term follow-up data from a 2010 multicenter study showed that after 2 years of cabergoline therapy with sustained prolactin normalization and significant tumor shrinkage, successful withdrawal of the drug (without prolactin rebound) occurred in 35% to 40% of patients [13]. Withdrawal should always be tapered over months, not stopped abruptly.

Special Populations: Pregnancy and Adolescents

Prolactin naturally rises throughout pregnancy, reaching 200 to 500 ng/mL at term. For women with known microprolactinomas who become pregnant, the Endocrine Society recommends discontinuing cabergoline or bromocriptine once pregnancy is confirmed, because the risk of clinically significant microprolactinoma growth during pregnancy is only about 2.6% [1]. Macroprolactinomas carry a 21% risk of symptomatic enlargement during pregnancy, so these patients require closer monitoring with monthly visual field checks and prolactin levels only if symptoms arise.

Bromocriptine has more long-term pregnancy safety data than cabergoline, but neither has been associated with increased rates of congenital malformations in registries exceeding 6,000 pregnancies combined [11].

Adolescents with hyperprolactinemia need particular attention to bone health. Estrogen or testosterone deficiency during the critical window of peak bone mass accrual (ages 14 to 25) can cause irreversible skeletal deficits. Early treatment and gonadal hormone monitoring are priorities in this population.

Patients on stable cabergoline therapy should have prolactin checked every 6 months and pituitary MRI repeated annually for the first 3 years, then every 2 to 3 years if the tumor is stable or shrinking [1].